



Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/Verified
CASPR2 Ab IgG Screen by IFA, Serum	Detected		[<1:10]	19-266-900130	23-Sep-19 11:37:00	23-Sep-19 11:37:00	23-Sep-19 11:39:08
CASPR2 Ab IgG Titer by IFA, Serum	1:20 *		[<1:10]	19-266-900130	23-Sep-19 11:37:00	23-Sep-19 11:37:00	23-Sep-19 11:39:13
LG11 Ab IgG Screen by IFA, Serum	Detected		[<1:10]	19-266-900130	23-Sep-19 11:37:00	23-Sep-19 11:37:00	23-Sep-19 11:39:08
LG11 Ab IgG Titer by IFA, Serum	1:40 *		[<1:10]	19-266-900130	23-Sep-19 11:37:00	23-Sep-19 11:37:00	23-Sep-19 11:39:13
Voltage-Gated Potassium Channel Ab, Ser	415 Hf	pmol/L	[0-31]	19-266-900130	23-Sep-19 11:37:00	23-Sep-19 11:37:00	23-Sep-19 11:38:40

23-Sep-19 11:37:00 CASPR2 Ab IgG Screen by IFA, Serum
 CASPR2 Antibody, IgG is detected. Titer results to follow.

23-Sep-19 11:37:00 LGI1 Ab IgG Screen by IFA, Serum
 LGI1 Antibody, IgG is detected. Titer results to follow.

23-Sep-19 11:37:00 Voltage-Gated Potassium Channel Ab, Ser:

Leucin-Rich, Glioma Inactivated Protein 1 Antibody, IgG and Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titers added.

23-Sep-19 11:37:00 CASPR2 Ab IgG Screen by IFA, Serum:
 INTERPRETIVE INFORMATION: CASPR2 Ab IgG w/Reflex to Titer,
 Serum

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy and Morvan syndrome. Tumors such as thymoma, small-cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

23-Sep-19 11:37:00 CASPR2 Ab IgG Titer by IFA, Serum:
 INTERPRETIVE INFORMATION: CASPR2 Ab Titer IgG by IFA,
 Serum

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

23-Sep-19 11:37:00 LGI1 Ab IgG Screen by IFA, Serum:
 INTERPRETIVE INFORMATION: LGI1 Ab IgG w/Reflex to Titer,
 Serum

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1 protein (LGI1) transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

23-Sep-19 11:37:00 LGI1 Ab IgG Titer by IFA, Serum:
INTERPRETIVE INFORMATION: LGI1 Ab Titer IgG by IFA,
Serum

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

23-Sep-19 11:37:00 Voltage-Gated Potassium Channel Ab, Ser:
INTERPRETIVE INFORMATION: Voltage-Gated Potassium Channel
(VGKC) Antibody, Serum

Negative 31 pmol/L or less
Indeterminate... 32 - 87 pmol/L
Positive 88 pmol/L or greater

Voltage-Gated Potassium Channel (VGKC) antibodies are associated with neuromuscular weakness as found in neuromyotonia (also known as Issacs syndrome) and Morvan syndrome. VGKC antibodies are also associated with paraneoplastic neurological syndromes and limbic encephalitis; however, VGKC antibody-associated limbic encephalitis may be associated with antibodies to leucine-rich, glioma-inactivated 1 protein (LGI1) or contactin-associated protein-2 (CASPR2) instead of potassium channel antigens. A substantial number of VGKC-antibody positive cases are negative for LGI1 and CASPR2 IgG autoantibodies, not all VGKC complex antigens are known. The clinical significance of this test can only be determined in conjunction with the patient's clinical history and related laboratory testing.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab